BioTime, Inc. (NYSEAMERICAN:BTX) shares were up 8.9% during trading on Thursday . The company traded as high as $2.20 and last traded at $2.09. Approximately 591,516 shares changed hands during mid-day trading, an increase of 25% from the average daily volume of 474,338 shares. The stock had previously closed at $1.92.

Separately, Zacks Investment Research downgraded BioTime from a “buy” rating to a “hold” rating in a report on Tuesday, July 24th.

BioTime (NYSEAMERICAN:BTX) last released its earnings results on Thursday, August 2nd. The biotechnology company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.03. BioTime had a return on equity of 30.68% and a net margin of 828.55%. The company had revenue of $2.55 million for the quarter, compared to the consensus estimate of $0.33 million.

Large investors have recently added to or reduced their stakes in the business. Schwab Charles Investment Management Inc. raised its position in shares of BioTime by 20.9% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 173,856 shares of the biotechnology company’s stock worth $468,000 after purchasing an additional 30,056 shares during the period. Bank of New York Mellon Corp raised its position in shares of BioTime by 4.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 744,554 shares of the biotechnology company’s stock worth $1,534,000 after purchasing an additional 33,350 shares during the period. Finally, Northern Trust Corp raised its position in shares of BioTime by 5.2% during the 1st quarter. Northern Trust Corp now owns 966,448 shares of the biotechnology company’s stock worth $2,600,000 after purchasing an additional 47,957 shares during the period.

BioTime Company Profile (NYSEAMERICAN:BTX)

BioTime, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies primarily in the United States and Israel. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; and Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy.

Featured Story: What is the NASDAQ Stock Market?

Receive News & Ratings for BioTime Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime and related companies with MarketBeat.com's FREE daily email newsletter.